Clinical Trials
18 trialsNCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT03609593 2026-02-25
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Columbia University
Phase 2 Completed
NCT02996773 2025-11-10
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Completed
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT01096992 2019-09-25
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01400685 2018-01-25
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Massachusetts General Hospital
Phase 1 Completed
NCT02194374 2017-06-12
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01466153 2017-05-31
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC
Phase 2 Completed
NCT01088984 2016-05-23
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00939328 2015-03-06
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00790855 2012-12-04
Bendamustine in Acute Leukemia and MDS
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01649622 2012-11-08
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01657955 2012-08-06
CLL
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01125787 2011-07-20
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Nevada Cancer Institute
Phase 2 Terminated
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn